Literature DB >> 16142671

Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box.

Chloe L Thio1, Mark S Sulkowski, David L Thomas.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16142671     DOI: 10.1086/496921

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  6 in total

1.  A case for treating high hepatitis B DNA levels before starting HIV therapy.

Authors:  Jason V Baker; David R Boulware; Paul R Bohjanen
Journal:  AIDS       Date:  2006-11-28       Impact factor: 4.177

2.  Management of HIV/HBV coinfection.

Authors:  Andy O Miller
Journal:  MedGenMed       Date:  2006-02-07

Review 3.  Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis.

Authors:  Robert M Grant
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

Review 4.  Management of hepatitis B virus co-infection on and off antiretroviral therapy.

Authors:  Vincent Soriano; Eugenia Vispo; Marcelle Bottecchia; Julie Sheldon; Paula Tuma; Javier Garcia-Samaniego; Pablo Barreiro
Journal:  Curr HIV/AIDS Rep       Date:  2008-05       Impact factor: 5.071

5.  THE PREVALENCE LIVER FUNCTION AND IMMUNOLOGIC STATUS OF CHILDREN WITH HIV AND HEPATITIS B VIRUS COINFECTION IN ENUGU, NIGERIA.

Authors:  Uleanya Nwachinemere Davidson; Nwokoye Ikenna Chidiebele; Emodi Ifeoma Josephine; Obidike Egbuna Olakunle; Ikefuna Anthony Nnaemeka; Eze Jude Chijioke; Ndu Ikenna Kingsley
Journal:  Afr J Infect Dis       Date:  2016-05-01

6.  The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.

Authors:  Marc M Solomon; Mauro Schechter; Albert Y Liu; Vanessa M McMahan; Juan V Guanira; Robert J Hance; Suwat Chariyalertsak; Kenneth H Mayer; Robert M Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2016-03-01       Impact factor: 3.731

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.